No room for cancellation, coasting, or ovarian hyperstimulation syndrome in oocyte donation cycles.
We retrospectively studied 429 IVF donor cycles in which ovulation was triggered with either hCG (175 cycles) or GnRH agonist (254 cycles). Of the donors in whom ovulation was triggered with hCG, 3.2% developed symptoms of moderate (2.2%) or severe (1%) ovarian hyperstimulation syndrome, while none of the IVF donor cycles that were triggered with the GnRH agonist presented ovarian hyperstimulation syndrome, needed coasting, or were cancelled.
Hernández
Eleuterio R
ER
Clínica FivMadrid, Madrid, Spain. ehernandezm@fivmadrid.es
Gómez-Palomares
José Luis
JL
Ricciarelli
Elisabetta
E
D000328:Adult; D006063:Chorionic Gonadotropin / Q000009:adverse effects* / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D005260:Female; D005307:Fertilization in Vitro / Q000009:adverse effects* / Q000379:methods*; D007987:Gonadotropin-Releasing Hormone / Q000819:agonists; D006801:Humans; D008186:Luteolytic Agents / Q000009:adverse effects / Q000494:pharmacology; D018587:Oocyte Donation / Q000009:adverse effects* / Q000379:methods*; D054315:Oocyte Retrieval / Q000379:methods; D016471:Ovarian Hyperstimulation Syndrome / Q000209:etiology*; D010060:Ovulation / Q000187:drug effects; D011247:Pregnancy; D018873:Pregnancy Rate; D012102:Reproductive Control Agents / Q000009:adverse effects / Q000494:pharmacology; D012189:Retrospective Studies; D017211:Treatment Failure; D017329:Triptorelin Pamoate / Q000009:adverse effects* / Q000494:pharmacology
D006063:Chorionic Gonadotropin; D008186:Luteolytic Agents; D012102:Reproductive Control Agents; D017329:Triptorelin Pamoate; D007987:Gonadotropin-Releasing Hormone